184 related articles for article (PubMed ID: 24774302)
1. Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome.
Fridley BL; Armasu SM; Cicek MS; Larson MC; Wang C; Winham SJ; Kalli KR; Koestler DC; Rider DN; Shridhar V; Olson JE; Cunningham JM; Goode EL
BMC Med Genomics; 2014 Apr; 7():21. PubMed ID: 24774302
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.
Winham SJ; Armasu SM; Cicek MS; Larson MC; Cunningham JM; Kalli KR; Fridley BL; Goode EL
Genet Epidemiol; 2014 Jul; 38(5):457-66. PubMed ID: 24853948
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.
Li L; Zheng H; Huang Y; Huang C; Zhang S; Tian J; Li P; Sood AK; Zhang W; Chen K
Carcinogenesis; 2017 Aug; 38(8):797-805. PubMed ID: 28637314
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer.
Koestler DC; Chalise P; Cicek MS; Cunningham JM; Armasu S; Larson MC; Chien J; Block M; Kalli KR; Sellers TA; Fridley BL; Goode EL
BMC Med Genomics; 2014 Jan; 7():8. PubMed ID: 24479488
[TBL] [Abstract][Full Text] [Related]
5. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
[TBL] [Abstract][Full Text] [Related]
6. Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer.
Wu D; Yang H; Winham SJ; Natanzon Y; Koestler DC; Luo T; Fridley BL; Goode EL; Zhang Y; Cui Y
J Hum Genet; 2018 Mar; 63(3):339-348. PubMed ID: 29321518
[TBL] [Abstract][Full Text] [Related]
7. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
8. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
9. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.
Akers SN; Moysich K; Zhang W; Collamat Lai G; Miller A; Lele S; Odunsi K; Karpf AR
Gynecol Oncol; 2014 Feb; 132(2):462-7. PubMed ID: 24374023
[TBL] [Abstract][Full Text] [Related]
10. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.
Chung VY; Tan TZ; Huang RL; Lai HC; Huang RY
Gene; 2017 Nov; 635():9-15. PubMed ID: 28887161
[TBL] [Abstract][Full Text] [Related]
11. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.
Dai W; Teodoridis JM; Zeller C; Graham J; Hersey J; Flanagan JM; Stronach E; Millan DW; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2011 Jun; 17(12):4052-62. PubMed ID: 21459799
[TBL] [Abstract][Full Text] [Related]
12. FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.
De La Chesnaye E; Méndez JP; López-Romero R; De Los Angeles Romero-Tlalolini M; Vergara MD; Salcedo M; Ojeda SR
Int J Clin Exp Pathol; 2015; 8(9):10192-203. PubMed ID: 26617728
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer.
Zhang LY; Li PL; Wang TZ; Zhang XC
Arch Gynecol Obstet; 2015 Oct; 292(4):891-7. PubMed ID: 25827305
[TBL] [Abstract][Full Text] [Related]
14. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.
Wang C; Cicek MS; Charbonneau B; Kalli KR; Armasu SM; Larson MC; Konecny GE; Winterhoff B; Fan JB; Bibikova M; Chien J; Shridhar V; Block MS; Hartmann LC; Visscher DW; Cunningham JM; Knutson KL; Fridley BL; Goode EL
Cancer Res; 2014 Jun; 74(11):3084-91. PubMed ID: 24728075
[TBL] [Abstract][Full Text] [Related]
15. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
16. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
[TBL] [Abstract][Full Text] [Related]
18. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.
Yang Y; Wu L; Shu X; Lu Y; Shu XO; Cai Q; Beeghly-Fadiel A; Li B; Ye F; Berchuck A; Anton-Culver H; Banerjee S; Benitez J; Bjørge L; Brenton JD; Butzow R; Campbell IG; Chang-Claude J; Chen K; Cook LS; Cramer DW; deFazio A; Dennis J; Doherty JA; Dörk T; Eccles DM; Edwards DV; Fasching PA; Fortner RT; Gayther SA; Giles GG; Glasspool RM; Goode EL; Goodman MT; Gronwald J; Harris HR; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Kar SP; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Koushik A; Lambrechts D; Le ND; Levine DA; Massuger LF; Matsuo K; May T; McNeish IA; Menon U; Modugno F; Monteiro AN; Moorman PG; Moysich KB; Ness RB; Nevanlinna H; Olsson H; Onland-Moret NC; Park SK; Paul J; Pearce CL; Pejovic T; Phelan CM; Pike MC; Ramus SJ; Riboli E; Rodriguez-Antona C; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Shan K; Siddiqui N; Sieh W; Stampfer MJ; Sutphen R; Swerdlow AJ; Szafron LM; Teo SH; Tworoger SS; Tyrer JP; Webb PM; Wentzensen N; White E; Willett WC; Wolk A; Woo YL; Wu AH; Yan L; Yannoukakos D; Chenevix-Trench G; Sellers TA; Pharoah PDP; Zheng W; Long J
Cancer Res; 2019 Feb; 79(3):505-517. PubMed ID: 30559148
[TBL] [Abstract][Full Text] [Related]
19. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Pradjatmo H; Dasuki D; Anwar M; Mubarika S; Harijadi
Asian Pac J Cancer Prev; 2014; 15(21):9479-85. PubMed ID: 25422243
[TBL] [Abstract][Full Text] [Related]
20. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
